Boult Wade Tennant
Bulletins » Two years down, five years to go until the end of the UPC transitional period

The transitional period for the Unified Patent Court (UPC) was initiated on 1 June 2023, the same date as the entry into force of the UPC Agreement. During this seven-year transitional period, due to end in mid-2030, but which may be prolonged for a further seven years:

  1. Applicants and proprietors have the opportunity to “opt-out” their European patent applications and “classical” European patents (i.e. “normal” nationally validated European patents, not those with unitary effect) from the jurisdiction of the UPC. In short, this opt-out lasts the entire lifetime of the patent, even after the end of the transitional period, and ensures that any litigation concerning the opted out “classical” European patent remains with the national courts.
  2. Actions for infringement or revocation in respect of a “classical” European patent may still be brought before national courts. If not opted out, then one may choose between the UPC and the national courts during this time.

Opting out or bringing an action before a national court during this period is not available for Unitary Patents. Please note that these issues affect only those “classical” European patents validated in EU member states participating in the UPC. European patents validated in non-participating EU states, such as Spain and Poland, and non-EU states, such as the UK and Switzerland, remain under the jurisdiction of the relevant national courts.

After the transitional period, i.e. from 1 June 2030, unless extended:

  1. Patentees will no longer be able to “opt-out” of the UPC. However, “classical” European patents already opted out will remain opted out, unless the opt-out is withdrawn.
  2. The UPC will automatically have exclusive jurisdiction over the relevant existing “classical” European patents or patent applications (that have not already been opted out), the relevant “classical” European patents or patent applications filed after the end of the transitional period, and (as during the transitional period) Unitary Patents. That is, unless already opted out, it will no longer be possible to bring an action before a national court in respect of a “classical” European patent in the relevant UPC states.

The EPO website records that unitary effect has been requested on 27.6% of European patents in 2025 to date (up from 25.6% in 2024 and 17.5% in 2023). This may indicate that the UPC is gaining trust from patentees during its first two years in action, in particular as case law continues to develop. Patentees may be taking solace from recent case law, some of which appears to indicate that the UPC intends to follow analogous tests to those developed by the EPO Boards of Appeal. Accordingly, it will be interesting to see whether there is a corresponding reduction in the number of opt-outs over the remaining five years.

It is worth remembering that you will not be able to “opt-out” forever, and it may be time to re-think your European validation strategy and/or accept your fate as regards the jurisdiction of the UPC.

In the meantime, if you would like to find out more about applying for a Unitary Patent or “opting out” of the UPC, please refer to our brochure or to contact one of our UPC Representatives.

Relevant sectors
Aerospace
  • Commercial aviation
  • Defence and security
  • Space and satellites
  • Unmanned aerial vehicles
Artificial Intelligence and Machine Learning
Automotive
  • Autonomous vehicles
  • Electric vehicles
  • Engines
Biotechnology
  • Antibody engineering
  • Antibody manufacture and formulation
  • Bioinformatics
  • Biosimilars
  • Drug delivery
  • Gene editing (e.g. CRISPR)
  • Genomic and molecular tools and methods
  • GM crops
  • Immuno-oncology (e.g. checkpoint inhibitors; modified T cells)
  • Next generation sequencing
  • Nucleic acid synthesis
  • Personalised medicine/disease biomarkers
  • Recombinant protein production and purification
  • Stem cell therapies
  • Supplementary protection certificates (SPCs)
  • Synthetic biology
  • Therapeutic antibodies
  • Vaccinology (e.g. viral vectors; mRNA vaccines)
  • Women’s health products
Chemicals
  • Agrochemicals
  • Catalysts
  • Dispersions and colloids
  • Lubricants
  • Polymers and plastics
Communications and Networks
  • Cloud computing
  • Internet of things (IOT)
  • Oceanography, marine
  • Wired and wireless networks
Computing and Software
  • Artificial intelligence and machine learning
  • Bioinformatics
  • Blockchain and distributed ledgers
  • Communications and networks
  • Computer games
  • Data and software security, cryptography and digital rights management (DRM)
  • Data management and storage, databases and data compression
  • Digital assistants, virtual assistants and software agents
  • Fintech and adtech
  • Machine vision
  • Metaverse, virtual reality (VR) and augmented reality (AR)
  • Motor capture
  • Multimedia, audio/video processing and animation
  • Natural language processing
  • Quantum computing
  • Robotic process automation
  • Search engines
  • Signal processing
  • Software applications and systems, mobile applications, user interfaces
Consumer Goods and Retail
  • Anti-counterfeit devices
  • Beauty
  • Fashion
  • Health, fitness and sport
  • Household goods
  • Luxury goods
  • Moda
  • Retail
Electronics and Electrical Devices
  • Computer and IT architecture and system design
  • Medical devices
  • Optics
  • Restaurants and bars
  • Robotics
  • Scientific instruments
  • Semiconductor devices
  • Testing systems, control systems, signal processing
  • Travel and leisure
  • Wearable tech and human interfaces
Energy and Green Technologies
  • Biofuels
  • Clean air
  • Fuel cells and battery technology
  • Renewables and recycling
  • Solar power
  • Water, oil and gas, nuclear, fusion, fission
  • Wind turbines
Food and Beverage
  • Beverages
  • Nutrition
  • Retail
Industrial Manufacturing and Processing
  • Packaging
  • Polymers and plastics
  • Printing tech
  • Additive manufacturing
  • Coatings
  • Construction
Materials
  • Advanced materials
  • Composite materials
  • Metallurgy and alloys
  • Nanotechnology
Medical Devices and Diagnostics
  • Artificial intelligence
  • Devices
  • Diagnostic instruments
  • Digital health
  • Drug delivery
  • Immuno-oncology
  • In vitro diagnostics
  • Medtech
Pharmaceuticals
  • Diagnostics
  • Drug delivery
  • Generic market entry
  • Medicinal chemistry
  • Methods of production and synthesis
  • Personalised medicine/disease biomarkers
  • Pharmaceutical formulations
  • Pharmaceuticalsceutical formulations
  • Polymorphs
  • Small molecule pharmaceuticals
  • Supplementary protection certificates (SPCs)
Trade Marks
  • Consumer goods
  • Cosmetics and perfumery
  • Financial services
  • Mechanical engineering
  • Mechanical products
  • Services
  • Telecommunications
Relevant sectors